Search clinical trials for: generic lopinavir/ritonavir

Total 8023 results

Prostate Cancer Clinical Trials Consortium
Memorial Sloan Kettering Cancer Center; Fred Hutchinson Cancer Center; Sidney... and other collaborators

Recruiting

PROMISE Registry: A Prostate Cancer Registry of Outcomes and Germline Mutations for Improved Survival and Treatment Effectiveness

Prostate Cancer

United States
Pfizer

Completed

Food Effect Study to Evaluate the Effect of High-Fat Meal on the Relative Bioavailability of PF-07321332 Boosted With Ritonavir in Healthy Adult Participants

Healthy Participants

United States
ANRS, Emerging Infectious Diseases
Institut National de la Santé Et de la Recherche Médicale, France

Completed

Prevention of Perinatal Transmission of HIV-1 Without Nucleoside Reverse Transcriptase Inhibitors (MONOGEST)

Maternal-fetal Infection Transmission

France
Hoffmann-La Roche

Completed

A Relative Bioavailability Study of Danoprevir and Ritonavir in Healthy Volunteers

Healthy Volunteer

New Zealand
Hoffmann-La Roche

Completed

A Study of Invirase (Saquinavir)/Ritonavir in HIV-Infected Infants and Children.

HIV Infections

Spain, Thailand, Argentina
The Third Xiangya Hospital of Central South University
Xiangya Hospital of Central South University

Unknown

Testing of HIV Protease Inhibitors to Suppress Inflammation and Improve Cardio Pulmonary Hemodynamics in Subjects With Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension

China
Hospitales Universitarios Virgen del Rocío

Completed

Darunavir Levels, Virological Efficacy, Proviral ADN and Resistances in Patients on Darunavir/Ritonavir Monotherapy (MonDar)

HIV-infection

Spain
ViiV Healthcare
GlaxoSmithKline

Completed

A Study To Assess GW433908 (Fosamprenavir) Containing Regimens In HIV-1 Infected Subjects

Infection, Human Immunodeficiency Virus

United States, Spain, France, United Kingdom, Chile, Brazil, Italy, Portugal
AbbVie

Completed

A Study to Evaluate Chronic Hepatitis C Infection in Adult Transplant Recipients (CORAL-I)

Chronic Hepatitis C Infection
University of California, San Francisco
Lazarex Cancer Foundation

Completed

Community-Based Health Coach to Improve Access to Germline Genetic Testing Among African American Men With Prostate Cancer

Prostate Carcinoma

United States
PATH
Seattle Children's Hospital; Komfo Anokye Teaching Hospital

Completed

Nifty Feeding Cup Versus Generic Medicine Cup Preterm Infants Who Have Difficulty Breastfeeding

Feeding; Difficult, Newborn | Infant,Premature

Ghana
CrystalGenomics, Inc.

Unknown

Examine Maximum Tolerated Dose and Pharmacokinetic and Pharmacodynamic Profile

Solid Tumour

Korea, Republic of
Pfizer

Completed

A Study to Learn About the Study Medicines (Nirmatrelvir Plus Ritonavir) in People Aged 12 Years or Older With COVID-19 and a Compromised Immune System

COVID-19

Spain, United States, Australia, Canada, Bulgaria, Slovakia, Mexico, Hungary, Brazil
Obafemi Awolowo University
University of Liverpool

Completed

Pharmacokinetic Interaction Between Nitazoxanide and Atazanavir/Ritonavir in Healthy Volunteers

Drug Interaction

Nigeria
American Research Corporation
AbbVie

Completed

A Study to Investigate HCV Response Rates in Real World Patients: HEARTLAND Study (HEARTLAND)

Chronic Hepatitis C
Hepa C

Completed

Effectiveness, Safety and Clinical Outcomes of Paritaprevir/Ombitasvir/r+Dasabuvir 8 Weeks (3D8)

Hepatitis C Infection

Spain
University of Modena and Reggio Emilia

Unknown

Efficacy Study to Evaluate the Effect of New Antiviral Drugs on HCV Infection.

Chronic Hepatitis, C Virus

Italy
Catholic University of the Sacred Heart

Completed

Atazanavir and Lamivudine for Treatment Simplification (AtLaS)

HIV Infections

Italy
Tibotec Pharmaceuticals, Ireland

Completed

A Study to Determine the Antiviral Activity of TMC310911 When Administered With Ritonavir in Treatment-Naive Human Immunodeficiency Virus - Type 1 (HIV-1) Infected Patients

Human Immunodeficiency Virus Type 1

Germany
Kenneth H. Mayer, MD
Bristol-Myers Squibb; Gilead Sciences; Abbott

Terminated

Safety and Acceptability Study of Non-occupational Prophylaxis (PEP) Following Potential Exposure to HIV (BMS PEP)

HIV

United States
Hamilton Health Sciences Corporation
Southlake Regional Health Centre; Federal Economic Development Agency for Southern... and other collaborators

Completed

The DNA-Based Lifestyle Enhancement Trial (DNAble)

Health Behavior | Cardiovascular Risk Factor | Genetic Information

Canada
Assistance Publique - Hôpitaux de Paris

Completed

Corpus Callosum Agenesis and Intellectual Disability (ACCREM)

Intellectual Deficiency | Cerebral Abnormality

France
Boston University
National Human Genome Research Institute (NHGRI)

Completed

Communicating Risk Information for Obesity

Obesity

United States
Federal University of São Paulo
Fundação de Amparo à Pesquisa do Estado de São Paulo

Completed

Therapeutic Equivalence Between Branded and Generic WARFArin Tablets in Brazil (WARFA)

Atrial Fibrillation

Brazil
Hadassah Medical Organization
Israel Association of Pediatricians

Completed

Omega-3 Supplementation and Attention-deficit-hyperactivity Disorder (ADHD)

Attention Deficit Hyperactivity Disorder

Israel
Assiut University

Active, not recruiting

Familial Hypercolerstremia as Risk Factor in Stemi Patient Who Underwent Ppci

Familial Hypercholesterolemia

Egypt
University Hospital, Bordeaux

Completed

Familial Analysis of Keratoconus Risk (AFRIK)

Keratoconus

France
Istituto Auxologico Italiano
Università Politecnica delle Marche; University of Milan

Completed

Effect on Energy Metabolism at Cellular Level of Diet Plus Treatment With Ephedrine and Caffeine in Obesity

Obesity

Italy
GB002, Inc.

Recruiting

Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)

Pulmonary Arterial Hypertension

United States, Spain, Israel, Korea, Republic of, Netherlands, France, Singapore, United Kingdom, Lithuania, Australia, Latvia, Argentina, Portugal, Greece, Czechia, Puerto Rico, Belgium, Italy, Poland, Romania, Serbia, Austria, Chile, Denma... and more
GB002, Inc., a wholly owned subsidiary of Gossamer...

Recruiting

Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)

Pulmonary Arterial Hypertension

United States, Australia, Spain, Czechia, France, Germany, United Kingdom, Belgium
GB002, Inc., a wholly owned subsidiary of Gossamer...

Completed

Clinical Study of Inhaled GB002 for Treatment of WHO Group I Pulmonary Arterial Hypertension (PAH)

Pulmonary Arterial Hypertension

United States, United Kingdom
Evidation Health
Sanofi Pasteur, a Sanofi Company

Completed

Influenza Vaccination Digital Interventions for People Living With Diabetes

Diabetes

United States
FitnessGenes Ltd.

Not yet recruiting

Use of Personalized Recommendations, Through Genetic and Lifestyle Data, to Improve Healthcare Staff Wellbeing

Well-Being, Psychological
Hospices Civils de Lyon

Unknown

Genetic Predisposition to Severe Forms of COVID-19 (SARS-CoV2 Infection) (COVIDGEN)

Covid19

France
University of Bath
Royal Devon and Exeter NHS Foundation Trust

Completed

Personalised HTO Versus Generic HTO Virtual Clinical Trial

Osteoarthritis, Knee

United Kingdom
Northwestern University
Georgetown University

Recruiting

APOL1 Genetic Testing Program for Living Donors

Chronic Kidney Diseases | Kidney Transplantation | Apolipoprotein L1

United States
IRCCS San Raffaele
Bristol-Myers Squibb

Completed

Efficacy of Atazanavir/Ritonavir Monotherapy as Maintenance in Patients With Viral Suppression

HIV-1 Infection

Italy
Pfizer

Completed

Renal Impairment Study of PF-07321332 Boosted With Ritonavir in Adult Participants With Renal Impairment and in Healthy Participants With Normal Renal Function.

Renal Impairment

United States
University of British Columbia

Completed

Switch to Unboosted Atazanavir With Tenofovir Study (SUAT)

HIV Infection

Canada
Assiut University

Completed

Evaluation of Treatment of Chronic HCV Patients in Chronic Kidney Disease Versus End Stage Renal Disease Patients

Hepatitis C

Egypt
Boehringer Ingelheim

Completed

Study of Pharmacokinetic Interaction Between Kaletra® (LPV/r) and BILR 355 BS Plus Ritonavir in Healthy Subjects

Healthy
Emory University

Completed

A Pharmacokinetic (PK) Study of a Combination of Indinavir, Ritonavir, and Amprenavir

HIV Infections

United States
Pfizer

Completed

A Study to Learn About a Repeat 5-Day Treatment With the Study Medicines (Called Nirmatrelvir/Ritonavir) in People 12 Years Old or Older With Return of COVID-19 Symptoms and SARS-CoV-2 Positivity After Finishing Treatment With Nirmatrelvir/Ritonavir

COVID-19

United States, Taiwan, Italy, Canada, Greece
Pfizer

Completed

A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection

COVID-19

United States, Russian Federation, Thailand, Czechia, Colombia, Bulgaria, Japan, South Africa, Turkey, Argentina, Hungary, Malaysia, Mexico, Poland, Spain, Ukraine, Brazil
Xiangao Jiang

Completed

Efficacy and Safety of Nirmatrelvir/Ritonavir for Treating Omicron Variant of COVID-19

Omicron Variant of COVID-19

China
Hoffmann-La Roche

Completed

A Study of The Relative Bioavailability of Ritonavir-Boosted Danoprevir Fixed Dose Combination Tablets in Healthy Volunteers

Healthy Volunteer

New Zealand
Boehringer Ingelheim

Completed

Bioequivalence Study of Tipranavir Stored at Controlled Temperature Compared With Tipranavir Stored at Controlled Refrigerated Conditions, Orally Co-administered With Ritonavir in Healthy Male and Female Volunteers

Healthy
Tibotec Pharmaceuticals, Ireland

Completed

A Study of Drug-drug Interaction Between Ritonavir and TMC435350 in Healthy Volunteers

Healthy

Belgium
Tibotec BVBA

Completed

VX-950-TiDP24-C124: A Phase I Trial to Investigate the Potential Pharmacokinetic Interactions Between Telaprevir and Darunavir/Ritonavir and Between Telaprevir and Fosamprenavir/Ritonavir at Steady-state.

Hepatitis C | HIV | Telaprevir
Bristol-Myers Squibb

Completed

Phase IIIb Study to Evaluate the Effectiveness and Safety of Atazanavir/Ritonavir as Single Enhanced Protease Inhibitor Therapy in Human Immunodeficiency Virus (HIV)-Infected Subjects Evidencing Virologic Suppression (OREY)

Human Immunodeficiency Virus (HIV) Infections

Spain

3

Subscribe